WebMay 30, 2024 · Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region 26 December 2024 Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA 7 February 2024 20 January 2024 Last reviewed on 30 May 2024 … WebWe are deeply committed to providing our customers with a broad range of essential medicines that physicians and pharmacists need to treat their patients. Because for us, …
Micro Diamond Round Floor Mat u0027s Tent Rugs …
WebApr 11, 2024 · Cisplatin is a chemotherapy drug that is commonly used for bladder cancer and improves the likelihood that surgery will be successful. It is the gold standard for treating certain forms of... WebDec 26, 2024 · In the United States, the Food and Drug Administration (FDA) is reviewing the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line … fischer houtdraadbout
US is facing a
WebJul 29, 2024 · Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have … Web2 days ago · Twelve drugmakers are in short supply of the product, and most told the ASHP they cannot estimate a resupply date. Hikma Pharmaceuticals and Sagent Pharmaceuticals each said they expect a release... WebIt offers 499 different medications in 1,256 different dosage strengths. Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax are some of the most popular products. Argatroban, fentanyl, phenylephrine, Robaxin, and iron gluconate are among the speciality injectable medications sold by Hikma in the United States, Europe, and MENA. fischer house lake providence la